Caseware UK (AP4) 2024.0.164 2024.0.164 2025-01-312025-01-312025-05-072024-02-01falsetrueNon-specialised wholesale trade2018trueThe members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.false 07305206 2024-02-01 2025-01-31 07305206 2023-02-01 2024-01-31 07305206 2025-01-31 07305206 2024-01-31 07305206 2023-02-01 07305206 c:Director3 2024-02-01 2025-01-31 07305206 d:PlantMachinery 2024-02-01 2025-01-31 07305206 d:PlantMachinery 2025-01-31 07305206 d:PlantMachinery 2024-01-31 07305206 d:PlantMachinery d:OwnedOrFreeholdAssets 2024-02-01 2025-01-31 07305206 d:MotorVehicles 2024-02-01 2025-01-31 07305206 d:MotorVehicles 2025-01-31 07305206 d:MotorVehicles 2024-01-31 07305206 d:MotorVehicles d:OwnedOrFreeholdAssets 2024-02-01 2025-01-31 07305206 d:OwnedOrFreeholdAssets 2024-02-01 2025-01-31 07305206 d:ComputerSoftware 2025-01-31 07305206 d:ComputerSoftware 2024-01-31 07305206 d:CurrentFinancialInstruments 2025-01-31 07305206 d:CurrentFinancialInstruments 2024-01-31 07305206 d:CurrentFinancialInstruments d:WithinOneYear 2025-01-31 07305206 d:CurrentFinancialInstruments d:WithinOneYear 2024-01-31 07305206 d:ShareCapital 2025-01-31 07305206 d:ShareCapital 2024-01-31 07305206 d:SharePremium 2025-01-31 07305206 d:SharePremium 2024-01-31 07305206 d:RetainedEarningsAccumulatedLosses 2025-01-31 07305206 d:RetainedEarningsAccumulatedLosses 2024-01-31 07305206 c:OrdinaryShareClass1 2024-02-01 2025-01-31 07305206 c:OrdinaryShareClass1 2025-01-31 07305206 c:OrdinaryShareClass1 2024-01-31 07305206 c:OrdinaryShareClass2 2024-02-01 2025-01-31 07305206 c:OrdinaryShareClass2 2025-01-31 07305206 c:OrdinaryShareClass2 2024-01-31 07305206 c:OrdinaryShareClass3 2024-02-01 2025-01-31 07305206 c:OrdinaryShareClass3 2025-01-31 07305206 c:OrdinaryShareClass3 2024-01-31 07305206 c:OrdinaryShareClass4 2024-02-01 2025-01-31 07305206 c:OrdinaryShareClass4 2025-01-31 07305206 c:OrdinaryShareClass4 2024-01-31 07305206 c:OrdinaryShareClass5 2024-02-01 2025-01-31 07305206 c:OrdinaryShareClass5 2025-01-31 07305206 c:OrdinaryShareClass5 2024-01-31 07305206 c:FRS102 2024-02-01 2025-01-31 07305206 c:AuditExempt-NoAccountantsReport 2024-02-01 2025-01-31 07305206 c:FullAccounts 2024-02-01 2025-01-31 07305206 c:PrivateLimitedCompanyLtd 2024-02-01 2025-01-31 07305206 d:WithinOneYear 2025-01-31 07305206 d:WithinOneYear 2024-01-31 07305206 d:BetweenOneFiveYears 2025-01-31 07305206 d:BetweenOneFiveYears 2024-01-31 07305206 d:ComputerSoftware d:ExternallyAcquiredIntangibleAssets 2024-02-01 2025-01-31 07305206 d:AcceleratedTaxDepreciationDeferredTax 2025-01-31 07305206 d:AcceleratedTaxDepreciationDeferredTax 2024-01-31 07305206 d:ComputerSoftware d:OwnedIntangibleAssets 2024-02-01 2025-01-31 07305206 e:PoundSterling 2024-02-01 2025-01-31 xbrli:shares iso4217:GBP xbrli:pure

Registered number: 07305206










PROCURE HEALTH LIMITED








UNAUDITED

FINANCIAL STATEMENTS

INFORMATION FOR FILING WITH THE REGISTRAR

FOR THE YEAR ENDED 31 JANUARY 2025

 
PROCURE HEALTH LIMITED
REGISTERED NUMBER: 07305206

BALANCE SHEET
AS AT 31 JANUARY 2025

2025
2024
Note
£
£

Fixed assets
  

Intangible assets
 4 
62,953
36,918

Tangible assets
 5 
39,027
48,887

  
101,980
85,805

Current assets
  

Stocks
 6 
393,183
459,616

Debtors: amounts falling due within one year
 7 
850,174
731,412

Cash at bank and in hand
 8 
111,344
55,055

  
1,354,701
1,246,083

Current liabilities
  

Creditors: amounts falling due within one year
 9 
(1,240,485)
(1,158,199)

Net current assets
  
 
 
114,216
 
 
87,884

Total assets less current liabilities
  
216,196
173,689

Provisions for liabilities
  

Deferred tax
 10 
(9,757)
(12,222)

Net assets
  
206,439
161,467


Capital and reserves
  

Called up share capital 
 11 
105
104

Share premium account
  
39,956
37,878

Profit and loss account
  
166,378
123,485

  
206,439
161,467


Page 1

 
PROCURE HEALTH LIMITED
REGISTERED NUMBER: 07305206

BALANCE SHEET (CONTINUED)
AS AT 31 JANUARY 2025

The directors consider that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the statement of comprehensive income in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf by: 




L Wilcox
Director

Date: 7 May 2025

The notes on pages 3 to 9 form part of these financial statements.

Page 2

 
PROCURE HEALTH LIMITED
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JANUARY 2025

1.


General information

ProCure Health Limited is a private company, limited by shares, registered in England and Wales, registration number. The registered office and principal place of business is Unit 5, Farmbrough Close, Aylesbury, Buckinghamshire, HP20 1DQ

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The following principal accounting policies have been applied:

 
2.2

Revenue

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised:

Sale of goods

Revenue from the sale of goods is recognised when all of the following conditions are satisfied:
the Company has transferred the significant risks and rewards of ownership to the buyer;
the Company retains neither continuing managerial involvement to the degree usually associated with ownership nor effective control over the goods sold;
the amount of revenue can be measured reliably;
it is probable that the Company will receive the consideration due under the transaction; and
the costs incurred or to be incurred in respect of the transaction can be measured reliably.

 
2.3

Pensions

Defined contribution pension plan

The Company operates a defined contribution plan for its employees. A defined contribution plan is a pension plan under which the Company pays fixed contributions into a separate entity. Once the contributions have been paid the Company has no further payment obligations.

The contributions are recognised as an expense in profit or loss when they fall due. Amounts not paid are shown in accruals as a liability in the Balance Sheet. The assets of the plan are held separately from the Company in independently administered funds.

Page 3

 
PROCURE HEALTH LIMITED
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JANUARY 2025

2.Accounting policies (continued)

 
2.4

Current and deferred taxation

The tax expense for the year comprises current and deferred tax. Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the balance sheet date in the countries where the Company operates and generates income.

Deferred tax balances are recognised in respect of all timing differences that have originated but not reversed by the balance sheet date, except that:
The recognition of deferred tax assets is limited to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits; and
Any deferred tax balances are reversed if and when all conditions for retaining associated tax allowances have been met.

Deferred tax balances are not recognised in respect of permanent differences except in respect of business combinations, when deferred tax is recognised on the differences between the fair values of assets acquired and the future tax deductions available for them and the differences between the fair values of liabilities acquired and the amount that will be assessed for tax. Deferred tax is determined using tax rates and laws that have been enacted or substantively enacted by the balance sheet date.


 
2.5

Intangible assets

Intangible assets are initially recognised at cost. After recognition, under the cost model, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

All intangible assets are considered to have a finite useful life. If a reliable estimate of the useful life cannot be made, the useful life shall not exceed ten years.

 
2.6

Tangible fixed assets

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives.

Depreciation is provided on the following basis:

Fixtures, fittings and equipment
-
10% reducing balance and 25% straight line
Motor vehicles
-
25% straight line

Page 4

 
PROCURE HEALTH LIMITED
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JANUARY 2025

2.Accounting policies (continued)

 
2.7

Stocks

Stocks are stated at the lower of cost and net realisable value, being the estimated selling price less costs to complete and sell. Cost is based on the cost of purchase on a first in, first out basis. Work in progress and finished goods include labour and attributable overheads.

At each balance sheet date, stocks are assessed for impairment. If stock is impaired, the carrying amount is reduced to its selling price less costs to complete and sell. The impairment loss is recognised immediately in profit or loss.

 
2.8

Debtors

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

 
2.9

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

 
2.10

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

 
2.11

Dividends

Equity dividends are recognised when they become legally payable. Interim equity dividends are recognised when paid. Final equity dividends are recognised when approved by the shareholders at an annual general meeting.


3.


Employees

The average monthly number of employees, including directors, during the year was 20 (2024 - 18).

Page 5

 
PROCURE HEALTH LIMITED
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JANUARY 2025

4.


Intangible assets




Computer software

£



Cost


At 1 February 2024
52,654


Additions
31,900



At 31 January 2025

84,554



Amortisation


At 1 February 2024
15,736


Charge for the year on owned assets
5,865



At 31 January 2025

21,601



Net book value



At 31 January 2025
62,953



At 31 January 2024
36,918



Page 6

 
PROCURE HEALTH LIMITED
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JANUARY 2025

5.


Tangible fixed assets





Fixtures, fittings and equipment
Motor vehicles
Total

£
£
£



Cost or valuation


At 1 February 2024
115,511
40,458
155,969


Additions
13,372
-
13,372



At 31 January 2025

128,883
40,458
169,341



Depreciation


At 1 February 2024
82,625
24,457
107,082


Charge for the year on owned assets
16,542
6,690
23,232



At 31 January 2025

99,167
31,147
130,314



Net book value



At 31 January 2025
29,716
9,311
39,027



At 31 January 2024
32,886
16,001
48,887


6.


Stocks

2025
2024
£
£

Raw materials and consumables
393,183
459,616



7.


Debtors

2025
2024
£
£


Trade debtors
786,489
645,322

Other debtors
-
4,488

Prepayments and accrued income
63,685
81,602

850,174
731,412


Page 7

 
PROCURE HEALTH LIMITED
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JANUARY 2025

8.


Cash and cash equivalents

2025
2024
£
£

Cash at bank and in hand
111,344
55,055



9.


Creditors: amounts falling due within one year

2025
2024
£
£

Trade creditors
743,955
736,230

Corporation tax
10,817
79,484

Other taxation and social security
40,105
57,289

Other creditors
425,755
260,865

Accruals and deferred income
19,853
24,331

1,240,485
1,158,199



10.


Deferred taxation




2025
2024


£

£






At beginning of year
(12,222)
(20,884)


Charged to profit or loss
2,465
8,662



At end of year
(9,757)
(12,222)

The provision for deferred taxation is made up as follows:

2025
2024
£
£


Accelerated capital allowances
(9,757)
(12,222)

Page 8

 
PROCURE HEALTH LIMITED
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JANUARY 2025

11.


Share capital

2025
2024
£
£
Allotted, called up and fully paid



2,777 (2024 - 2,777) Ordinary A shares of £0.001 each
3
3
1,794 (2024 - 1,554) Ordinary B shares of £0.001 each
2
1
35,000 (2024 - 35,000) Ordinary C shares of £0.001 each
35
35
15,000 (2024 - 15,000) Ordinary D shares of £0.001 each
15
15
35,000 (2024 - 35,000) Ordinary E shares of £0.001 each
35
35
15,000 (2024 - 15,000) Ordinary F shares of £0.001 each
15
15

105

104


During the year, the Company issued 240 Ordinary B shares with a nominal value of £0.001 each for a total consideration of £2,079.


12.


Pension commitments

The Company operates a defined contributions pension scheme. The assets of the scheme are held separately from those of the Company  in an independently administered fund. The pension cost charge represents contributions payable by the Company  to the fund and amounted to £11,621 (2024: £34,217). Contributions totalling £2,151 (2024: £1,282) were payable to the fund at the balance sheet date and are included in creditors.


13.


Commitments under operating leases

At 31 January 2025 the Company had future minimum lease payments due under non-cancellable operating leases for each of the following periods:

2025
2024
£
£


Not later than 1 year
44,434
76,172

Later than 1 year and not later than 5 years
-
44,434

44,434
120,606


Page 9